Galapagos hits brakes on lupus CAR-T, trims 100 jobs
23 Feb 2024
Phase 2ASHFinancial StatementPhase 1
Belgian biotech Galapagos announced that it has discontinued development of its CD19 CAR-T project GLPG5101 for refractory systemic lupus erythematosus (rSLE), citing unspecified "strategic reasons." The company said in its 2023 financial results presentation that it also cut approximately 100 positions across the organisation to align with a "renewed focus on innovation."
Last August, Galapagos said it had filed an application in Europe to start Phase I development of its CD19 CAR-T candidate in patients with refractory SLE, but provided few other details since. That development has now been halted, although GLPG5101 remains in Phase II testing for relapsed/refractory non-Hodgkin's lymphoma (NHL), according to the company's website.
At the American Society of Hematology (ASH) conference late last year, the company reported that 6 of 7 evaluable NHL patients responded to treatment with GLPG5101 in the Phase II ATALANTA-1 study, including 4 who achieved complete responses. It said the therapy also had "an encouraging safety profile."
Meanwhile, Galapagos has another programme in SLE, a TYK2 inhibitorTYK2 inhibitor dubbed GLPG3667 that is currently in mid-stage development.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.